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An analog of the anticancer drug cisplatin (mtPt)
was delivered to mitochondria of human cells using
a peptide specifically targeting this organelle.
mtPt induces apoptosis without damaging nuclear
DNA, indicating that mtDNA damage is sufficient
to mediate the activity of a platinum-based chemo-
therapeutic. This study demonstrates the specific
delivery of a platinum drug to mitochondria and in-
vestigates the effects of directing this agent outside
the nucleus.
INTRODUCTION
cis-diamminedichloroplatinum(II), or cisplatin, is an effective
chemotherapeutic agent that is used in nearly 50% of all cancer
patients (Galanski et al., 2005). The second generation platinum-
based drugs, carboplatin and oxaliplatin, also play an important
role inmodern chemotherapy. These compounds bind to nuclear
DNA, resulting primarily in intrastrand DNA crosslinks (Todd and
Lippard, 2009). The lesions they cause inhibit transcription, ulti-
mately triggering apoptosis and cell death (Todd and Lippard,
2009). It is important, however, to understand whether alter-
native cellular targets besides nuclear DNA can potentiate the
activity of platinum-based drugs because they offer the opportu-
nity to treat resistant tumors. Furthermore, a greater understand-
ing of other platinum drug targets might allow treatment-limiting
side effects to be mitigated.
Owing to their central role in facilitating apoptosis, mitochon-
dria are being actively explored as potential anticancer drug
targets (Fulda et al., 2010). Mitochondria contain their own
circular DNA (mtDNA), the potential importance of which as a
target during platinum-based chemotherapy has not been fully
evaluated. Previous studies have proposed mitochondrial and
not nuclear DNA as the critical target of cisplatin in potentiating
its anticancer activity (Cullen et al., 2007), and under certain
conditions higher levels of cisplatin adducts are observed in
mitochondrial relative to nuclear DNA (Murata et al., 1990;
Olivero et al., 1995). Mitochondria also appear to play a role in
mediating cellular resistance to cisplatin. Cisplatin-resistantChemistry & Biology 20, 1323–132cell lines have elevated mitochondrial membrane potentials
(Andrews and Albright, 1992; Isonishi et al., 2001), sustain less
damage to mtDNA when treated with the drug (Hirama et al.,
2006), and exhibit substantially less mitochondrial uptake of
cisplatin (Groessl et al., 2011) compared to nonresistant parent
lines.
To investigate more precisely the effects of mitochondrial tar-
geting by a potential platinum chemotherapeutic, we designed
a complex that would selectively localize to this organelle. A
mitochondria-penetrating peptide (MPP) was appended to the
cis-{Pt(NH3)2}
2+ DNA-binding unit of cisplatin and carboplatin.
MPPs are short, cell-permeable peptide sequences comprising
alternating lipophilic and cationic residues that exhibit minimal
toxicity toward human cells (Horton et al., 2008; Yousif et al.,
2009). Here, we describe the synthesis and biological properties
of a platinum(II) complex conjugated to the N terminus of an
MPP to determine the effect of mitochondrial targeting on the
activity of a platinum-based agent. This study probes the
consequences of platinum directed specifically to mitochondria
in a cancer cell.
Platinum-peptide conjugates reported previously use a variety
of different linking strategies. Such conjugates have been pre-
pared by attaching the peptide to the nonleaving group ligand
(amine) of a platinum(II) complex (Robillard et al., 2000; Barraga´n
et al., 2009; Damian et al., 2010), the leaving group ligand
(carboxylate) of a platinum(II) complex (Ndinguri et al., 2009),
or through axial ligands of a platinum(IV) prodrug (Mukhopad-
hyay et al., 2008; Graf et al., 2012). Here, we began with the plat-
inum(II) complex [Pt(succac)(NH3)2](NO3), where succac equals
succinylacetonate, as detailed in the Supplemental Information
(available online). Structural and spectroscopic characterization
data for this complex are shown in Figure S1. The succac ligand
contains (1) a b-diketonate group for coordination to platinum as
the leaving group ligand, and (2) a dangling carboxylic acid
functionality for amide-bond formation. [Pt(succac)(NH3)2](NO3)
was conjugated to the N terminus of the MPP r(Fxr)3, where
r and Fx are the unnatural amino acid residues D-arginine and
L-cyclohexylalanine, respectively. This peptide was selected
for conjugation because it exhibits no toxicity toward human
cells (Horton et al., 2012), is composed of artificial amino
acids, and is therefore not degraded by proteases (Fonseca
et al., 2011). This peptide/platinum conjugate is referred to as
mtPt (Figure 1A). A fluorophore-labeled analog, mtPt-TAMRA8, November 21, 2013 ª2013 Elsevier Ltd All rights reserved 1323
Figure 1. mtPt Localizes to Mitochondria
and Is Active against a Cisplatin-Resistant
Cell Line
(A) Structure of mtPt.
(B) Structures of cis-[Pt(NH3)2Cl2] (cisplatin) and
[Pt(NH3)2(acac)]
+.
(C) Intracellular localization of mtPt-TAMRA in
HeLa cells by fluorescence microscopy.
(D) Cytotoxicity of mtPt. Viability of A2780 WT and
cisplatin-resistant A2780CP70 cells treated for
72 hr with mtPt. Mean values plotted, nR 3, error
bars represent SEM.
See also Note S1A, Table S1, and Figure S1 for
further information on the characterization of the
compounds tested.
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tetramethylrhodamine (TAMRA) on the amino side chain of a
C-terminal lysine. For both compounds, the platinum unit was
attached while these peptides remained on the solid-phase
support. The peptides were then cleaved from the resin with
neat trifluoroacetic acid (TFA) and purified by reverse-phase
high-performance liquid chromatography (HPLC). The purified
Pt-peptide conjugates were characterized by ESI-MS and
195Pt nuclear magnetic resonance (NMR) spectroscopy (Notes
S1B and S1C; Figures S1 and S2). The ability to tether cis-di-
ammineplatinum(II) groups to peptides on the solid-phase via
linkages in their leaving groups using [Pt(succac)(NH3)2](NO3)
represents a general strategy for the design of platinum-peptide
conjugates.
In order to assess the intracellular localization of mtPt, fluores-
cence imaging studies were carried out with the TAMRA-labeled1324 Chemistry & Biology 20, 1323–1328, November 21, 2013 ª2013 Elsevier Ltd All rights reanalog. Localization was first assessed in
HeLa cells, for they have a well-defined
mitochondrial network that can be readily
imaged. Representative images revealing
colocalization of the TAMRA conjugate
with MitoTracker Deep Red (Invitrogen)
are shown in Figure 1C. Imaging was
also performed in wild-type (WT) A2780
and cisplatin-resistant A2780 CP70
ovarian cancer cell lines. Pearson’s corre-
lation coefficients (PCCs) quantitatively
describing colocalization of the two dyes
in these cell lines are given in Table S2.
For both cell lines, mtPt(TAMRA) localizes
specifically to themitochondriawithPCCs
ranging from 0.36 to 0.53. These results
also clearly indicate that mtPt(TAMRA)
doesnot localize in thenucleus; Pearson’s
correlation coefficients for overlap with
the nuclear stain are all effectively zero.
The cytotoxicity of mtPt was then
studied using the MTT assay in A2780
WT and A2780CP70 ovarian cancer cell
lines. Cisplatin, [Pt(NH3)2(acac)]
+, and
[Pt(succac)(NH3)2]
+ were included as
controls. The results are summarized in
Table S1 and Figure S3, and representa-tive dose-response curves for mtPt are depicted in Figure 1D.
Cisplatin is toxic to A2780 cells at submicromolar concentra-
tions, with an IC50 of 0.60 ± 0.08 mM. In the resistant CP70 line,
however, the IC50 value (5.2 ± 1.4 mM) increases by almost an
order of magnitude. The calculation of resistance factors (RFs),
defined as the ratios of IC50 values of resistant to wild-type cell
lines, provides an estimate of differential toxicity. The RF for
cisplatin is 8.7, indicating that it is susceptible to resistance
factors expressed in A2780CP70 cells. [Pt(acac)(NH3)2]
+ and
[Pt(succac)(NH3)2]
+ are both less toxic than cisplatin (IC50 values
of 13.9 ± 1.9 and 220 ± 40 mM, respectively), but exhibit similar
resistance factors. The lower toxicity for the latter two com-
pounds is expected, given that chelating b-diketonate ligands
decrease the rate of departure of the leaving group from the
platinum coordination sphere, which leads to lower biological
activity (Wilson and Lippard, 2012). The toxicity of mtPt is greaterserved
Figure 2. The Cellular Effects of mtPt Treatment
(A) DNA damage caused by platinum drugs. Relative amplification of an 8.9 kb mitochondrial specific gene segment is reduced by 6 hr of treatment with 15 mM
mtPt but not by 30 mM treatment with [Pt(acac)(NH3)2](SO4)0.5 (acac-Pt) or 15 mM treatment with cisplatin. Mean values plotted, n = 4, all values normalized to
nontreated control. Error bars represent SEM. *p < 0.05; **p < 0.01.
(B) Cell-cycle arrest caused by platinum drugs. In contrast to cisplatin and the parent compound, mtPt does not induce cell-cycle arrest. Quantitative analysis
of distribution into G1, S, and G2 cell-cycle phases was assessed by propidium iodide staining and flow cytometry. Mean values plotted, n = 3. Error bars
represent SEM.
(C) Assessment of mitochondrial ROS production by MitoSox staining of A2780 cells treated with the indicated concentrations of mtPt and
[Pt(acac)(NH3)2](SO4)0.5 (acac-Pt) for 24 hr. Mean values plotted, n = 3, all values normalized to nontreated control. Error bars represent SEM.
(D) mtPt induces slow-onset apoptosis. Annexin V/Sytox Red staining of A2780 cells treated with 30 mM mtPt at indicated time points.
See also Figure S2.
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of 7.5 ± 0.3 mM, but importantly, the activity is unaffected in
the resistant cell line (Figure 1D). The mechanisms used by this
cell line to evade the action of platinum drugs, including
increased nucleotide excision repair and drug efflux (Parker
et al., 1991), are presumably less able to interfere with the
action of a drug that targetsmitochondria, allowingmtPt to retain
activity in both cell lines.
Further links between the activity of mtPt and events occurring
within mitochondria were sought by assessing DNA damage,
effects on cell cycle, and the generation of mitochondrial
reactive oxygen species. Damage to nuclear and mitochondrial
DNA was assessed by monitoring the efficiency of PCR
amplification of long segments of isolated nuclear and mito-
chondrial DNA. A2780 cells were exposed to mtPt, [Pt(acac)
(NH3)2](SO4)0.5, or cisplatin for 6 hr. PCR amplification of an
8.9 kb mitochondrial genomic segment and a 12.2 kb nuclear
genomic segment was analyzed and compared to results for
untreated controls. mtPt caused a statistically significant
reduction in the amplification of the mitochondrial but not
the nuclear DNA segment (Figure 2A). The reverse effect was
observed for cisplatin (Figure 2A). These results indicate that
mtPt damages mitochondrial DNA without causing a signifi-
cant amount of lesions on nuclear DNA. This conclusion wasChemistry & Biology 20, 1323–132corroborated by flow cytometry studies, which revealed that
mtPt does not induce cell-cycle arrest in A2780 cells (Figures
2B and S4). The genomic DNA-targeting compounds cisplatin
and [Pt(acac)(NH3)2](SO4)0.5, in contrast, both induced signifi-
cant cell-cycle arrest. Although the mechanism of action for
mtPt is clearly different from that of platinum drugs acting in the
nucleus, apoptotic cell death still occurs, as judged by Annexin
V/Sytox staining and flow cytometry (Figures 2D and S5).
Damage to mitochondrial DNA can produce reactive oxygen
species (ROS) that lead to mitochondrial dysfunction and cell
death (Santos et al., 2003). We therefore assessed whether
mtPt treatment increases the levels of superoxide in mitochon-
dria. mtPt induced significant increases in mitochondrial super-
oxide in A2780 cells following 24 hr of treatment, as judged
by studies using a fluorogenic dye that is specific for O2
– ROS.
The [Pt(acac)(NH3)2](SO4)0.5 parent compound, in contrast,
caused minimal superoxide production (Figure 2C). These re-
sults support the hypothesis that mtPt generates mitochondrial
dysfunction.
To further probe a potential connection between damage
to mitochondrial DNA and mtPt cytotoxicity, we assessed mtPt
activity in mouse embryonic fibroblasts (MEFs) expressing a
form of mitochondrial DNA polymerase gamma (PolG) lacking
functional 30- to 50-exonuclease activity. The PolG m/m line is8, November 21, 2013 ª2013 Elsevier Ltd All rights reserved 1325
Figure 3. Cells with Defective DNA Pol g Are Sensitized to mtPt
(A) Representative distribution of Pol G WT and Pol G m/m cells into alive, early apoptotic and late apoptotic populations after 24 hr. In these trials, 30 mMmtPt
and 10 mM cisplatin were used. Populations assessed by Annexin V/Sytox staining and flow cytometry.
(B and C) Quantitation of apoptotic cell death in Pol G WT and mutant m/m cells. Mean values plotted, n = 3. All error bars represent SEM.
See also Figure S3.
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at a 3- to 5-fold higher rate than their WT counterparts (Kujoth
et al., 2005). We therefore hypothesized that theymight be highly
sensitive to agents that damage mtDNA. Indeed, we observed
that PolG m/m cells are more sensitive to mtPt than wild-type
cells, with greater levels of apoptosis being generated at
an equivalent dose (Figure 3). This potentiation of toxicity was
not observed for cisplatin or [Pt(acac)(NH3)2](SO4)0.5 (Figures 3
and S6). These data suggest that mtPt-induced apoptosis
results from damage specifically to mtDNA.SIGNIFICANCE
In summary, we have prepared and characterized a mito-
chondrially localized conjugate of cisplatin using chemistry
that can be readily applied to access a wide range of plati-
num(II)-peptide conjugates targeted to subcellular locales.
Although less cytotoxic than cisplatin, presumably owing
to slower ligand exchange kinetics, mtPt is equally effective
at killing wild-type and cisplatin-resistant ovarian cancer
cells. We find that mtPt is delivered to mitochondria and
damages mtDNA. Moreover, we present evidence that a
cell line with reduced mitochondrial genomic integrity is
highly sensitive to treatment with mtPt, linking its activity
directly to mtDNA damage. Nuclear DNA damage and cell-1326 Chemistry & Biology 20, 1323–1328, November 21, 2013 ª2013cycle arrest, bothwell-characterized aspects of the cisplatin
mechanism of action, were not observed for the mitochon-
drially-targeted compound. These findings provide direct
evidence that damage to mtDNA by platinum chemothera-
peutics is toxic to cancer cells and indicate that mitochon-
dria are potential targets for anticancer therapy.EXPERIMENTAL PROCEDURES
General Materials and Methods
Succinylacetone (Levenson, 1994) and [Pt(acac)(NH3)2](SO4)0.5 (Wilson and
Lippard, 2012) were synthesized as previously described. Peptides
were also prepared as reported (Mourtada et al., 2013) and purified by
reverse-phase HPLC. Other reagents were purchased from commercial
vendors.
Physical Measurements
NMR spectra were acquired on a Bruker DPX-400 spectrometer in the
Massachusetts Institute of Technology (MIT) Department of Chemistry
Instrumentation Facility (DCIF). For Fourier transform infrared spectroscopy
(FTIR) spectra, samples were prepared as KBr disks and data were recorded
with a ThermoNicolet Avatar 360 spectrophotometer running the OMNIC
software. Electrospray ionization mass spectrometry (ESI-MS) measure-
ments were acquired on an Agilent Technologies 1100 series LC-MSD
trap. Solutions used for biological studies were dissolved in MilliQ water
(or PBS for cisplatin) and sterile-filtered. The platinum concentrations
of the solutions were determined by graphite-furnace atomic absorption
spectroscopy (GFAAS) using a Perkin-Elmer AAnalyst600 spectrometer.Elsevier Ltd All rights reserved
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Cisplatin (500 mg, 1.67 mmol) and AgNO3 (552 mg, 3.25 mmol) were stirred in
10 ml H2O in the absence of light at room temperature for 16 hr. The resulting
mixture was filtered to remove AgCl. To the filtrate, a solution of NaOH (67 mg,
1.68 mmol) and succinylacetone (269 mg, 1.70 mmol) in 5 ml of H2O was
added dropwise. After stirring at room temperature (RT) for 5 hr, the resulting
solution was concentrated to dryness at 60C under reduced pressure to
afford an orange oil. This oil was dissolved in 3 ml of H2O and acidified with
three drops of 25% HNO3. Acetone (50 ml) was added, and the resulting
turbid white suspension was stirred for 3 min, resulting in the deposition of
an oily orange-brown residue. The turbid supernatant was decanted and
mixed with 50 ml of a 1:1 (v/v) mixture of acetone and diethyl ether. Upon
stirring at RT for 5 min, an orange-brown residue deposited again. The
cloudy supernatant was decanted and poured directly into 150 ml of diethyl
ether. The mixture was stored at –40C for 1.5 hr and filtered to collect a
white solid. The white solid was washed with 2 3 10 ml diethyl ether and
then dried in vacuo. The yield equals 203 mg (28%). Characterization data
are given in Note S1A.
Synthesis of mtPt
A 50-mmol portion of FMOC-r(Fxr)3 on Rink amide resin was placed in a
fritted 2.5 ml Torviq disposable syringe and swelled with 2 ml of anhydrous
DMF for 1 hr. The N-terminal FMOC group was removed by treating the
resin with a solution of 25% 4-methylpiperidine in DMF (v/v) for 30 min.
The deprotected resin was washed with 5 3 1.5 ml DMF. A mixture of
90 mg (200 mmol) [Pt(NH3)2(succac)]NO3 and 76 mg (200 mmol) HATU
was dissolved in 1.5 ml of 10% N,N-diisopropylethylamine (DIPEA) in dime-
thylformamide (DMF) (v/v) and added to the deprotected resin. The reaction
vessel was shaken at RT for 60 min, then washed sequentially with 5 3
1.5 ml of DMF and 5 3 1.5 ml CH2Cl2 and dried in vacuo. The dry resin
was treated with a TFA/water/triisopropylsilane 95/2.5/2.5% (v/v) solution
for 90 min to detach mtPt. mtPt was precipitated from the cleavage solution
with diethyl ether. The resulting solid mtPt was separated by centrifugation
and purified by semipreparative HPLC with a C18 reverse-phase column
(9.4 mm 3 250 mm). Fractions from sequential runs containing mtPt were
pooled and lyophilized. The purity of the final product was assessed via
analytical HPLC. Purification conditions and characterization data is given
in Note S1B.
Synthesis of mtPt-TAMRA
A 50-mmol portion of FMOC-r(Fxr)3K-MTT was deprotected in a 3% solution of
TFA in DCM for 30 min and coupled to (5,6)-TAMRA using four equivalents
(5,6)-TAMRA, four equivalents HBTU, and eight equivalents DIPEA in DMF
for 2 hr. The resulting resin was labeled with 200 mmol (90 mg) of [Pt(NH3)2(suc-
cac)]NO3 using the procedure described above for the preparation of mtPt.
The purity of the two isomers (5 and 6) of mtPt-TAMRA was assessed by
analytical HPLC. The 5-isomer (tr = 26.5 min), R 95% pure based on the
integrated chromatogram, was carried forward for biological studies. The
distinction between the 5-isomer and 6-isomer was made based on 1H-
NMR spectroscopy (Figure S1H). Characterization is given in Note S1C.
X-Ray Crystallography
Single crystals of succinylacetone and [Pt(succac)(NH3)2](NO3) were grown
from hexanes/Et2O and MeOH/Et2O, respectively. Data were obtained,
solved, and refined as previously described (Wilson and Lippard, 2012).
Refinement data and thermal ellipsoid plots are given in Table S3 and
Figure S1. These data have been deposited in the Cambridge Crystallo-
graphic Data Centre (CCDC) under the accession codes of CCDC 938791
and 938792 for succinylacetone and [Pt(succac)(NH3)2](NO3), respectively.
Cell Culture
A2780 and A2780CP70 (wild-type and cisplatin-resistant ovarian cancer) cell
lines were obtained from Fox Chase Cancer Center and cultured in RPMI-
1640 medium supplemented with 10% FBS and 1% penicillin/streptomycin.
PolG WT and m/m MEFs were cultured in high glucose DMEM supplemented
with 10% FBS. The cells were incubated in a humidified atmosphere contain-
ing 5% CO2 at 37
C.Chemistry & Biology 20, 1323–132Cytotoxicity Assays
The colorimetric MTT assaywas used to assess cytotoxicity of the compounds
using a previously described protocol (Wilson and Lippard, 2012). From the
resulting dose-response curves, 50% growth inhibitory concentration (IC50)
values were determined by interpolation.
Cell Imaging Studies
A2780 and A2780CP70 cells were seeded in an imaging dish in 2 ml of growth
medium at 60% confluence. The growth medium was swapped with premixed
medium containing 1 or 10 mM of mtPt-TAMRA, and the cells were allowed to
incubate with the dye for 1 hr. MitoTracker Green and Hoechst 33258, were
added to the cells at 1.25–2.5 mM concentrations and allowed to incubate
for 30 min. At the end of the incubation period, the medium was aspirated,
and the cells were washed with 3 3 1 ml PBS and submerged in 2 ml of
dye-free DMEM. The imaging experiments were performed using a Zeiss
Axiovert 200M inverted epifluorescence microscope equipped with an
EM-CCD digital camera (Hamamatsu) and a MS200 XY Piezo Z stage (Applied
Scientific Instruments). The light source was an X-Cite 120 metal-halide lamp
(EXFO), and the fluorescence images were obtained with an oil-immersion
objective at 633magnification. The microscope was operated by the Volocity
software program of Perkin-Elmer. Colocalization of the dyes was quantitated
using the program ImageJ (Schneider et al., 2012) using a previously described
protocol (French et al., 2008). HeLa cells were imaged using a previously
described protocol (Fonseca et al., 2011).
Analysis of Mitochondrial Superoxide Levels
A2780 cells were plated in 12-well plates at a density of 105 cells/ml and
allowed to attach overnight. Cells were then treated with the indicated con-
centrations of mtPt and [Pt(acac)(NH3)2](SO4)0.5 and incubated for 24 or
48 hr. The medium was removed and cells were washed with Hank’s buffered
saline (HBS) and then incubated with 5 mM MitoSox reagent (Invitrogen) in
HBS for 30 min in the absence of light. Cells were washed three times
with HBS, harvested by trypsinization, and analyzed via flow cytometry with
FACSCanto. At least 104 cells were analyzed for each sample.
Annexin V Apoptosis Assay
A2780 cells were plated in a 12-well dish at a density of 105 cells/ml and
allowed to adhere overnight. PolG WT and m/m cells were plated at a density
of 5 3 104 cells/well. A2780 Cells were treated with the indicated concen-
trations of mtPt for 90 min, 8 hr, and 24 hr. PolG WT and m/m cells were incu-
bated for 24 hr. Following incubation, cells were stained at room temperature
with Annexin V-FITC for 15 min and 5 nM Sytox Red for an additional 15 min.
Analysis was performed via flow cytometry with FACSCanto. At least 104 cells
were analyzed for each sample.
Cell Cycle Analysis
A2780 cells were seeded in a 12-well dish at a density of 105 cells/mL and
allowed to adhere overnight. Cells were treated with the indicated concen-
trations of mtPt and [Pt(acac)(NH3)2](SO4)0.5 and incubated for 24 hr. Cells
were harvested by trypsinization and fixed at 4C in 70% ethanol for 2 hr. Cells
were centrifuged, ethanol was removed, and the remaining cell pellet was
washed once with PBS. Cells were resuspended in PBS and incubated with
0.2 mg/mL RNase A for 1 hr at 37C, then stained with 10 mg/ml propidium
iodide and analyzed immediately via flow cytometry with FACSCanto. Quanti-
tation of data was performed using FlowJo. At least 104 cells were analyzed
for each sample.
Determination of DNA Damage by qPCR
A2780 cells were seeded at 23 105 cells/well and allowed to adhere overnight.
Cells were treated with either 15 mM mtPt, 30 mM [Pt(acac)(NH3)2](SO4)0.5, or
15 mM cisplatin for 6 hr and harvested after trypsinization. DNA was isolated
from cell pellets using the Sigma GenElute mammalian genomic DNAminiprep
kit according to the manufacturer’s instructions. Amplification of an 8.9 kb
segment of mitochondrial DNA or a 12.2 kb segment of genomic DNA was
performed using the Elongase long range PCR enzyme kit (Invitrogen) as
described previously (Santos et al., 2006). Quantitation of amplified product
was performed by Pico Green staining and normalized to nontreated value.8, November 21, 2013 ª2013 Elsevier Ltd All rights reserved 1327
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